Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anastrozole is a nonsteroidal aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It works by inhibiting the enzyme aromatase, which is responsible for converting androgens to estrogens, thereby reducing estrogen levels in the body. This reduction slows or stops the growth of estrogen-dependent breast cancer cells. Anastrozole is also used as a first-line treatment for advanced or metastatic breast cancer and can be prescribed to prevent breast cancer in women at high risk. The drug is taken orally as a 1 mg tablet once daily[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anastrozole.